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Background: Microalbuminuria is an early marker of chronic kidney disease (CKD). Previous studies have shown
that either metabolic syndrome (MetS) or chronic inflammation is related to renal impairment. The aim of this study
was to investigate the association between MetS, C-reactive protein (CRP) and microalbuminuria in a rural Chinese
population.
Methods: This was a cross-sectional study using data from the Handan Eye Study. MetS was defined according to
the Chinese Diabetes Society (CDS) criteria. CRP levels ≥ 3 mg/L were classified as high CRP. Microalbuminuria was
defined as a urinary albumin/creatinine ratio (ACR) of 30–300 mg/g.
Results: We included 4191 subjects aged ≥ 30 years in this analysis. The prevalence of MetS and microalbuminuria
in the group was 25.7% and 15.6%, respectively. The odds ratio (OR) of microalbuminuria in subjects with MetS was
1.25 (95% confidence interval (CI): 1.03 − 1.51) compared with those without microalbuminuria. In multivariate
logistic regression analysis, high blood pressure (OR 1.36, 95% CI: 1.10 − 1.67) and high fasting blood glucose (OR
1.44, 95% CI: 1.17 − 1.76) were independently associated with microalbuminuria. Subjects with high CRP and MetS
had a 1.46-fold greater risk of having microalbuminuria compared with those with low CRP without MetS (95% CI:
1.06 − 2.01).
Conclusions: In this rural Chinese population aged ≥30 years, MetS and microalbuminuria were independently
related and the combination of high CRP and MetS was associated with an increased risk of microalbuminuria.
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Chronic kidney disease (CKD) has become a worldwide
public health problem and microalbuminuria is an early
marker of CKD. Many studies have shown that
microalbuminuria is a strong and independent predictor
of progressive kidney disease, cardiovascular events and
all-cause mortality in diabetic, non-diabetic, hypertensive
persons, and even in the general population [1-5]. There-
fore, early prevention and treatment of microalbuminuria,
by inhibiting the renin-angiotensin system, is generally* Correspondence: huangw@trhos.com; wningli@vip.163.com
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reproduction in any medium, provided the orrecommended in high risk patients, such as those with dia-
betes or hypertension [6]. Furthermore, identification and
treatment of the risk factors for microalbuminuria may be
an effective approach to prevent adverse outcomes.
Metabolic syndrome (MetS) is a common disorder cha-
racterized by abdominal obesity, hypertriglyceridemia, low
high density lipoprotein (HDL) cholesterol level, high
blood pressure (BP), and high fasting blood glucose level.
A previous national cross-sectional study reported that
the prevalence of MetS was 15.1% in Chinese adults aged
35–74 years [7]. Further, previous studies have shown that
MetS is associated with microalbuminuria [8-10].
C-reactive protein (CRP) has been recognized as a sensi-
tive marker of inflammation. Some cross-sectional studies
have found a significant correlation between CRP andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ever, other studies found conflicting results [13,14].
Studies examining the relationship between CRP and
microalbuminuria in Chinese populations are rare. Re-
cently, we reported that a high prevalence of microal-
buminuria (15.3%) was observed in a rural Chinese
population aged ≥ 30 years [15]. The aim of the current
study was to investigate the association between MetS,




The Handan Eye Study (HES) was a population-based,
cross-sectional study conducted from October 2006 to
October 2007, which was designed to survey eye diseases
and other health-related problems. Detailed information
on this study has been published elsewhere [16]. In brief,
residents of Yongnian County, Handan city, Hebei
province, China, aged ≥ 30 years were randomly selected
using a stratified, clustered and multi-staged sampling
technique. Yongnian County is located approximately
500 km south of Beijing and covers 980 km2. The total
population was 830 000 in 2005; 90% of the population
were farmers; and 98% were Han. Thirteen of the 458
villages in Yongnian County were randomly selected to
achieve a target sample size of 8653, with 7557 participants
considered eligible; 6830 underwent a comprehensive eye
examination. Data from 4191 participants aged ≥ 30 years
were complete and included in this study. The HES
protocol was approved by the Beijing TongRen Hospital
Ethical Committee and conformed to the Declaration of
Helsinki. All subjects gave written informed consent.
Data collection
Sociodemographic characteristics (age, sex and education),
medical history (hypertension, diabetes and cardiovascular
disease or stroke), and lifestyle behavior (smoking status
and alcohol intake) were obtained using questionnaires.
Height, weight and waist circumference were measured
according to standard protocols. Body mass index (BMI)
was calculated from weight and height measurements as
weight (kg) divided by the square of the height (m2). BP
was measured twice in a sitting position after at least
5 minutes’ rest. An average of the two readings was then
calculated. Blood specimens were collected after an over-
night fast of at least 8 hours. Serum creatinine (SCr) was
measured using a kinetic Jaffe reaction. Glucose, trigly-
cerides and HDL cholesterol were measured by enzymatic
methods using an automatic clinical chemistry analyzer
(Olympus AU2700, Tokyo, Japan). High-sensitivity CRP
was measured using immunonephelometry with the
IMMAGE Immunochemistry System (Beckman Coulter,
Inc., Fullerton, CA, USA). Fresh midstream urine wascollected in the morning and women who were actively
menstruating were excluded from the urine test. Urine
albumin concentration was measured by immunotur-
bidimetry (Audit Diagnostics, Cork, Ireland). Urine
creatinine was measured by the same method used for
SCr.
Definitions
MetS was confirmed according to the Chinese Diabetes
Society (CDS) criteria when a subject had three or more of
the following five components [17]: 1) obesity: BMI ≥
25 kg/m2; 2) fasting blood glucose ≥ 6.1 mmol/L or recei-
ving antidiabetic medication; 3) triglycerides ≥ 1.7 mmol/L;
4) HDL cholesterol < 1.04 mmol/L; and 5) BP ≥ 130/
85 mmHg or receiving antihypertensive medication. We
also analyzed data on central obesity, defined as waist
circumference > 90 cm in men or > 80 cm in women
according to the American Heart Association/National
Heart, Lung, and Blood Institute Scientific Statement
(AHA/NHLBI) [18]. A CRP cutoff of 3 mg/L was used to
differentiate high and low CRP groups according to the
American Heart Association/Centers for Disease Control
(AHA/CDC) consensus [19]. Subjects with clinical inflam-
mation (CRP levels > 10 mg/L) were excluded from this
study. Urinary albumin/creatinine ratios (ACR) of 30–
300 mg/g and < 30 mg/g were defined as microalbuminuria
and normoalbuminuria, respectively. Participants with
macroalbuminuria (ACR > 300 mg/g) were excluded. We
repeated the analysis using gender-specific definitions of
microalbuminuria (17–250 mg/g for men and 25–355 mg/g
for women) based on the National Kidney Foundation
guidelines [20].
Hypertension was defined as systolic BP ≥ 140 mm Hg
or diastolic BP ≥ 90 mm Hg, or receiving antihypertensive
medication. Diabetes was defined as fasting blood glu-
cose ≥ 7.0 mmol/L or a self-reported history of diabetes.
Statistical analysis
All analyses were performed using SPSS software, ver-
sion 11.5 (SPSS, Inc., Chicago, IL, USA). Data are
presented as the mean ± SD for continuous variables and
as proportions for categorical variables. Appropriate
variables were compared using the unpaired t test for
continuous data and χ2 test for categorical data. Because
the CRP distribution was skewed, variables are expressed
as medians and interquartile ranges and were compared
using the Mann–Whitney test. We calculated the fre-
quency of the individual MetS components, MetS and
high CRP. The association between MetS, CRP and
microalbuminuria was analysed using univariate and
multivariate logistic regression analysis. The odds ratio
(OR) of microalbuminuria was calculated according to
the CRP levels and MetS status and a 95% confidence
interval (CI) was obtained using a multiple logistic
Jiang et al. BMC Nephrology 2013, 14:118 Page 3 of 7
http://www.biomedcentral.com/1471-2369/14/118regression model. We also used multivariate linear re-
gression analysis to estimate the association between
CRP levels (independent variable) and urinary ACR
(dependent variable). All reported p values are based on
two-sided tests and p < 0.05 was considered significant.Results
Baseline characteristics
A total of 4191 participants were studied; 55.4% (n = 2320)
were female and the mean age was 51.7 ± 11.1 years. The
prevalence of microalbuminuria in this rural Chinese
population aged ≥ 30 years was 15.6%. Table 1 shows the
baseline characteristics according to the microalbuminuria
status. Compared with the normoalbuminuria group, the
microalbuminuria group had a greater age; higher waist
circumference; history of cardiovascular disease; and
higher systolic BP; diastolic BP; fasting blood glucose;Table 1 Basic patient characteristics according to microalbum
Total Norm
n = 4191 n = 3
Age (y) 51.7 ± 11.1 51.1 ±
Female, No. (%) 2320(55.4) 1919
Current smoker, No. (%) 1078(26.0) 929(2
Current drinker, No. (%) 774(18.7) 659(1
High school education, No. (%) 132(3.2) 110(3
Cardiovascular disease, No. (%) 207(4.9) 162(4
Stroke, No. (%) 101(2.4) 89(2.5
BMI (kg/m2) 24.7 ± 3.7 24.7 ±
Waist circumference (cm) 87.9 ± 9.6 87.7 ±
Systolic BP (mm Hg) 139.4 ± 22.1 138.1
Diastolic BP(mm Hg) 77.7 ± 12.2 77.3 ±
Fasting glucose (mmol/L) 5.8 ± 1.3 5.7 ±
Triglycerides (mmol/L) 1.5 ± 1.0 1.5 ±
HDL cholesterol (mmol/L) 1.3 ± 0.3 1.3 ±
SCr (umol/L) 71.4 ± 10.8 71.5 ±
Diabetes, No. (%) 259(6.2) 195(5
Hypertension, No. (%) 2076(49.5) 1672
CRP (mg/L) 0.8(0.4-2.1) 0.8(0.
High CRP †, No. (%) 660(15.7) 535(1
Obesity, No. (%) 1737(41.4) 1467
High BP, No. (%) 2723(65.0 ) 2233
High fasting glucose, No. (%) 818(19.5) 643(1
High triglycerides, No. (%) 1185(28.3) 982(2
Low HDL cholesterol, No. (%) 797(19.0) 677(1
MetS ‡, No. (%) 1076(25.7) 873(2
BMI body mass index, BP blood pressure, CRP C-reactive protein, HDL high density l
* Microalbuminuria was defined as a urinary albumin/creatinine ratio (ACR) of 30–3
† High CRP was defined as a CRP ≥3 mg/dl.
‡ MetS was defined by the Chinese Diabetes Society (CDS).triglycerides; and CRP levels. Hypertension, diabetes and
female gender were prevalent among subjects with
microalbuminuria.
A total of 1076 (25.7%) subjects had MetS; 41.4% were
obese; 65.0% had high BP; 19.5% had high fasting glucose;
28.3% had high triglycerides; and 19.0% had low HDL
cholesterol. High CRP (≥ 3 mg/L) was observed in 660
(15.7%) subjects. The prevalence of MetS and high CRP
was higher in subjects with microalbuminuria than in
those with normoalbuminuria (31.1% vs. 24.7%, p = 0.001
and 19.1% vs. 15.1%, p = 0.01).Association between MetS, CRP and microalbuminuria
Table 2 shows the ORs for microalbuminuria by individual
MetS component, MetS and high CRP. In the unadjusted
regression analysis, high BP (OR 1.76, 95% CI: 1.45 − 2.12)
and high fasting blood glucose (OR 1.65, 95% CI: 1.36 −inuria status
oalbuminuria Microalbuminuria * p value
538 n = 653







3.7 24.7 ± 3.8 0.96
9.6 88.8 ± 9.5 0.009
± 21.5 146.4 ± 24.4 <0.001
12.0 80.1 ± 13.2 <0.001
1.2 6.1 ± 1.9 <0.001
0.9 1.6 ± 1.3 <0.001
0.2 1.3 ± 0.3 0.33











ipoprotein, MetS metabolic syndrome, SCr serum creatinine.
00 mg/g.
Table 2 Odds ratios for microalbuminuria by individual MetS component, MetS and CRP
Unadjusted Adjusted model1* Adjusted model2†
OR (95% CI) p value OR (95% CI) p value OR (95%CI) p value
Obesity 1.00(0.84-1.18) 0.96 0.98(0.82-1.17) 0.81 0.92(0.76-1.10) 0.34
High BP 1.76(1.45-2.12) <0.001 1.38(1.13– 1.70) 0.002 1.36(1.10– 1.67) 0.004
High fasting glucose 1.65(1.36-1.99) <0.001 1.47(1.20 -1.80) <0.001 1.44(1.17 -1.76) <0.001
High triglycerides 1.17(0.98-1.41) 0.08 1.10(0.91-1.32) 0.35 1.03(0.85-1.26) 0.76
Low HDL cholesterol 1.95( 0.77-1.18) 0.65 1.03(0.83 -1.29) 0.77 1.04(0.82 -1.30) 0.76
High CRP 1.33(1.07-1.65) 0.01 1.16(0.93-1.45) 0.19 1.12(0.89-1.40) 0.34
MetS‡ 1.38(1.15-1.65) 0.001 1.25(1.03 -1.51) 0.02 — —
BP blood pressure, CRP C-reactive protein, CI confidence interval, HDL high density lipoprotein, MetS metabolic syndrome, OR odds ratio.
* Adjusted for age, sex, smoking status, alcohol use, education level, history of cardiovascular disease or stroke and CRP (except for analyses on the High CRP).
† Additionally adjusted for the other components of MetS.
‡ Compared with those without MetS (<3 components).
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adjusting for age, sex, smoking status, alcohol use, educa-
tion level, history of cardiovascular disease or stroke and
CRP, the associations were still significant. Adjusting for
the components of MetS had little effect on the ORs. In
the multivariate logistic regression model, MetS was inde-
pendently associated with microalbuminuria (OR 1.25,
95% CI: 1.03 − 1.51, p = 0.02); however, the association
between high CRP and microalbuminuria disappeared after
adjustments were made for age, sex, and other possible risk
factors for CKD (p = 0.34). A similar result was observed in
the multivariate linear regression analysis; after adjusting
for age, sex and the components of MetS, there was no re-
lationship between CRP and urinary ACR (p = 0.78).
Interrelationship between MetS, CRP and
microalbuminuria
Table 3 shows the ORs for microalbuminuria by CRP levels
and MetS status. The prevalence of microalbuminuria in
each group was as follows: low CRP without MetS, 14.2%;
high CRP without MetS, 16.3%; low CRP with MetS,
17.6%; and high CRP with MetS, 22.8%. There was no sig-
nificant difference between the low CRP without MetS and
high CRP without MetS groups (14.2% vs. 16.3%, p = 0.26)
as well as between the low CRP with MetS and high CRP
with MetS groups (17.6% vs. 22.8%, p = 0.06). Compared
with the low CRP without MetS group, the multivariateTable 3 Odds ratios for microalbuminuria by CRP levels and M
N Microalbuminuria
N. (%)
Low CRP without MetS 2723 386(14.2)
High CRP without MetS 392 64(16.3)
Low CRP with MetS 808 142(17.6)
High CRP with MetS 268 61(22.8)
CRP C-reactive protein, CI confidence interval, MetS metabolic syndrome, OR odds r
*Adjusted for age, sex, smoking status, alcohol use, education level, history of cardiadjusted OR for microalbuminuria was 1.23 (95% CI:
0.99 − 1.52) and 1.05 (95% CI: 0.78 − 1.42) in the high
CRP without MetS and low CRP with MetS groups,
respectively. Subjects with high CRP and MetS had a
1.46-fold increase in OR for microalbuminuria (95% CI:
1.06 − 2.01, p = 0.02).
Sensitivity analysis
First, we included 4180 subjects with complete informa-
tion in the analysis of central obesity. The prevalence of
MetS and microalbuminuria was 30.1% (n = 1259) and
15.5% (n = 649), respectively and there was a strong and
independent relationship between MetS and microal-
buminuria after further adjustments (OR 1.40, 95% CI:
1.17 − 1.68, p < 0.001).
Second, the results were similar when gender-specific
microalbuminuria cutoffs were applied; a total of 1076
(23.2%) subjects had microalbuminuria. In the multivariate-
adjusted model, MetS was independently associated with
microalbuminuria (OR 1.23, 95% CI: 1.05 − 1.45, p = 0.01),
and we found no relationship between CRP and microal-
buminuria (p = 0.14). Subjects with high CRP and MetS
had a 1.37-fold greater risk of having microalbuminuria
compared with those with low CRP without MetS (95% CI:
1.03 − 1.82, p = 0.03).
Third, after excluding subjects with hypertension, the
prevalence of MetS and microalbuminuria decreasedetS status
Unadjusted Multivariate-adjusted*
OR (95% CI) p value OR (95%CI) p value
reference reference
1.29(1.05-1.59) 0.02 1.23(0.99-1.52) 0.07
1.09(0.91-1.26) 0.26 1.05(0.78-1.42) 0.74
1.78(1.32-2.42) <0.001 1.46(1.06-2.01) 0.02
atio.
ovascular disease or stroke.
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11.8%, respectively and MetS was not significantly
associated with microalbuminuria (OR 1.01, 95% CI:
0.67 − 1.53, p = 0.98).
Discussion
In this rural Chinese population aged ≥ 30 years, we found
that MetS, as defined by the CDS, was independently as-
sociated with microalbuminuria after adjusting for age,
sex and other potential confounding factors. High BP and
high fasting blood glucose were the two main risk factors.
In addition, we found that CRP was not related to
microalbuminuria in the multivariate analysis; however,
the combination of high CRP and MetS increased the risk
of microalbuminuria.
We used ACR to assess microalbuminuria in our study.
The prevalence of microalbuminuria in this rural popula-
tion was 15.6%, higher than other population-based
studies in the US (6.4% in 5659 adults aged 20–80 years in
the National Health and Nutrition Examination Survey
(NHANES III)) [8], Japan (13.7% in 2321 participants aged
40–87 years) [9] and China (5.3 − 11.5%) [10,21-24]. No-
tably, the reports from Chinese urban regions showed that
the prevalence of microalbuminuria was 5.3% in Beijing
(2310 adults aged ≥ 40 years) [21]; 5.8% in Guangzhou
(6311 adults aged ≥ 20 years) [22]; 6.7% in Shanghai (3532
adults aged ≥ 20 years) [23]; 8.8% in Hangzhou (2969
adults aged 18 − 87 years) [24]; and 11.5% in Taiwan (2311
adults aged ≥ 40 years) [10]. The discrepancy may be due
to differences in the sample size and population studied,
including factors such as age, race, region or other factors.
The prevalence of MetS in our study was 25.7%, lower
than two urban population studies in Beijing (34.1%)
[21] and Taiwan (39.1%) [10], and higher than a recent
study in Hangzhou (12.6%) [24]. The difference between
urban and rural populations may be partly due to
different age groups, geographic regions or definitions of
MetS. Our study identified a positive relationship bet-
ween MetS and microalbuminuria in the rural Chinese
adult population, which was compatible with previous
studies. Nevertheless, the association between the spe-
cific MetS components and microalbuminuria in these
populations was inconsistent. Studies in the US and
Japan reported that high BP, high fasting blood glucose
and obesity were associated with microalbuminuria [8,9].
The results from two Chinese studies demonstrated that
all MetS components were associated with microal-
buminuria [10,24]. In our study, high BP and high
fasting blood glucose were independent risk factors for
microalbuminuria, and no association between other
MetS components and microalbuminuria was seen. A
similar result was obtained in a Chinese urban popula-
tion study [23]. High BP and high fasting blood glucose
are two important components of MetS. As previouslyreported, our study revealed that mildly elevated BP
(≥ 130/85 mm Hg) or fasting blood glucose levels
(≥ 6.1 mmol/l) were independently associated with
microalbuminuria. Based on these findings, we can easily
identify subjects who are at risk of microalbuminuria by
measuring BP and fasting blood glucose level. In addition,
sensitivity analysis revealed that the observed correlation
between MetS and microalbuminuria was strongly
affected by the presence of hypertension, which may be at-
tributed to the high prevalence of hypertension (49.5%) in
the present study, higher than previous reports from
Beijing (47.1%) [21] and southern China (19.2%) [22]. The
reason for this may be the different age groups, cardiovas-
cular risk factors or lifestyle and dietary patterns which
could potentially affect blood pressure. Hypertension may
be an important threat for microalbuminuria in this rural
population.
Although several epidemiological studies have con-
firmed the relationship between MetS and microal-
buminuria, the underlying mechanisms are still not
completely understood. Several possible reasons have
been proposed, including insulin resistance, inflamma-
tion, renal endothelial dysfunction, altered renal hemo-
dynamics, and others [25]. The results of our and other
studies have shown that CRP, a widely used marker of
chronic inflammation, was strongly related to MetS
[26-29]. Data from population-based studies from the
US [11], Japan [12] and Singapore [30] have shown that
CRP was associated with microalbuminuria. These fin-
dings suggest that inflammation may play an important
role in early kidney damage. However, even though
15.7% of subjects had high CRP levels (≥ 3 mg/L) in our
study, a relationship between high CRP and microal-
buminuria was not seen. This is similar to previous
reports showing that CRP was associated with decreased
renal function but not albuminuria [13], or that microal-
buminuria was related to a different marker of inflam-
mation (e.g., fibrinogen) but not CRP in a logistic
regression model [14]. We also examined the interrela-
tionship between CRP and MetS and the results showed
that only the combination of high CRP and MetS was
independently associated with microalbuminuria (OR
1.46, 95% CI: 1.05 − 2.01) after further adjustments. Our
findings are supported by a recent study indicating that
the odds for CKD (defined as an estimated glomerular
filtration rate (eGFR) < 60 ml/min/1.73 m2) increased
only in the subgroup having both high CRP and MetS
[31]. In another study, CRP was associated with CKD
(defined as an eGFR < 60 ml/min/1.73 m2 or albumi-
nuria) independent of MetS, and subjects with high CRP
and MetS had the highest odds for CKD of the four
groups [32]. These results suggest a positive interrela-
tionship between these MetS and CRP, and microal-
buminuria. One consideration is that inflammation and
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damage.
This study had a number of limitations. First, a causal
relationship cannot be established between MetS and
microalbuminuria because of the cross-sectional study
design. Second, the ACR measurement was based on a
single spot urine sample, which could result in misclassifi-
cation of the microalbuminuria status. However, this simple
sampling procedure was commonly used in epidemiologic
studies. Third, several studies have reported that statin
drugs may decrease the CRP levels [33,34]. We did not
control for the effect of statin drugs in this study, because
the number of statin users was relatively small. Only 1.7%
(n = 71) of participants answered whether lipid-lowering
drugs were being taken during the study period. Finally,
selection bias might, in theory, have influenced our results.
Conclusions
In conclusion, our study showed that MetS was asso-
ciated with microalbuminuria in a rural Chinese popula-
tion aged ≥ 30 years. Despite a lack of an independent
association between CRP and microalbuminuria, high
CRP combined with MetS increased the risk of microal-
buminuria. Further prospective cohort studies are neces-
sary to clarify these causal relationships.
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